title: Rosiglitazone: a European regulatory perspective.
authors.affiliation: European Medicines Agency, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK. eberhard.blind@ema.europa.eu
authors.forename: E
authors.initials: E
authors.lastname: Blind
authors.forename: K
authors.initials: K
authors.lastname: Dunder
authors.forename: P A
authors.initials: PA
authors.lastname: de Graeff
authors.forename: E
authors.initials: E
authors.lastname: Abadie
mesh_terms: D002319:Cardiovascular System / Q000187:drug effects; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone